Hyaluronic acid-based nanoparticles loaded with curcumin and ranibizumab for treating keratitis and anti-neovascularization.

Authors: Bao, Qingdong^1,2, Zheng, Yi², Lu, Bingkun², Li, Guangwei^1,2, Dong, Muchen^1,2, dongmuchen1988@163.com

Source: Materials Technology; Dec2024, Vol. 39 Issue 1, p1-8, 8p

Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration.

Authors: Eckardt, Franziska¹ (AUTHOR) Franziska.eckardt@med.uni-muenchen.de, Lorger, Anna¹ (AUTHOR), Hafner, Michael¹ (AUTHOR), Klaas, Julian Elias¹ (AUTHOR), Schworm, Benedikt¹ (AUTHOR), Kreutzer, Thomas Christian¹ (AUTHOR), Priglinger, Siegfried Georg¹ (AUTHOR), Siedlecki, Jakob¹ (AUTHOR)

Source: Scientific Reports. 4/26/2024, Vol. 14 Issue 1, p1-9. 9p.

Subject Terms: *RANIBIZUMAB, *MACULAR degeneration, *CHOROID, *COMBINED modality therapy, *AFLIBERCEPT, *VASCULAR endothelial growth factor antagonists, *SUBGROUP analysis (Experimental design)

Ranibizumab Port Delivery System in Neovascular Age-Related Macular Degeneration: Where Do We Stand? Overview of Pharmacokinetics, Clinical Results, and Future Directions.

Authors: Carlà, Matteo Mario^1,2 (AUTHOR) mariacristina.savastano@gmail.com, Savastano, Maria Cristina^1,2 (AUTHOR) francescoboselli@outlook.it, Boselli, Francesco^1,2 (AUTHOR) federico.giannuzzi@gmail.com, Giannuzzi, Federico^1,2 (AUTHOR) stanislao.rizzo@gmail.com, Rizzo, Stanislao^1,2 (AUTHOR)

Source: Pharmaceutics. Mar2024, Vol. 16 Issue 3, p314. 13p.

Subject Terms: *MACULAR degeneration, *RANIBIZUMAB, *INTRAVITREAL injections, *INTRAOCULAR drug administration, *PHARMACOKINETICS

Intravitreal Injection Rates for Neovascular Age-Related Macular Degeneration in Australia During the 2020 COVID-19 Lockdowns.

Authors: Phakey, Sachin¹ (AUTHOR), Hall, Anthony J^2,3 (AUTHOR), Lim, Lyndell L^1,4 (AUTHOR) limllp@unimelb.edu.au

Source: Ophthalmic Epidemiology. Feb2024, Vol. 31 Issue 1, p94-97. 4p.

Subject Terms: *RANIBIZUMAB, *MACULAR degeneration, *COVID-19 pandemic, *STAY-at-home orders, *INTRAVITREAL injections, *ENDOTHELIAL growth factors

Geographic Terms: VICTORIA, AUSTRALIA

Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab.

Authors: Almuiña-Varela, Pablo^1,2 (AUTHOR) lauragarqu@gmail.com, García-Quintanilla, Laura^2,3 (AUTHOR), Rodríguez-Cid, María José¹ (AUTHOR) maricardo@live.com, Gil-Martínez, María^1,2 (AUTHOR) mariagilmtez@hotmail.com, Abraldes, Maximino J.^1,4,5 (AUTHOR) franciscogomez-ulla@institutogomez-ulla.es, Gómez-Ulla, Francisco⁴ (AUTHOR), Estany-Gestal, Ana⁶ (AUTHOR) ana.estany.gestal@sergas.es, Alcántara-Espinosa, Jorge Miguel⁶ (AUTHOR) jorge.alcantara.espinosa@hotmail.com, Fernández-Rodríguez, Maribel^1,4,5 (AUTHOR) maribelfernandez@institutogomez-ulla.es, Fernández-Ferreiro, Anxo^2,3 (AUTHOR) maribelfernandez@institutogomez-ulla.es

Source: Pharmaceuticals (14248247). Feb2024, Vol. 17 Issue 2, p157. 17p.

Subject Terms: *MACULAR degeneration, *RANIBIZUMAB, *VISUAL acuity

Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema.

Authors: Mahapatra, Santosh K.¹ santu_k74@rediffmail.com, Parhi, Anjalika², Shree, Pallavi², Mohanty, Anuja¹

Source: Indian Journal of Ophthalmology. 2024 Supplement, Vol. 72, pS106-S110. 5p.

Subject Terms: *MACULAR edema, *RANIBIZUMAB, *VISUAL acuity, *DEXAMETHASONE, *EYE inflammation

The effect of different forms of intravitreal ranibizumab administration on pain.

Authors: Coskun, Mehmet¹ mdmehmetcoskun@gmail.com

Source: Annals of Medical of Research. Jun2024, Vol. 31 Issue 6, p456-458. 3p.

Subject Terms: *INTRAVITREAL injections, *RANIBIZUMAB, *PAIN management, *STATISTICAL significance, *DIABETIC retinopathy, *MACULAR edema, *EYE drops

Use of Ranibizumab for evaluating focal laser combination therapy for refractory diabetic macular edema patients: an exploratory study on the RELAND trials.

Authors: Hatano, Makoto¹ (AUTHOR), Wakuta, Makiko¹ (AUTHOR), Yamamoto, Kazutaka² (AUTHOR), Arai, Eika³ (AUTHOR), Enoki, Miho⁴ (AUTHOR), Fujimoto, Kazushi⁵ (AUTHOR), Yamauchi, Kazuhiko⁶ (AUTHOR), Ishikawa, Keijiro⁷ (AUTHOR), Sonoda, Koh-Hei⁷ (AUTHOR), Kimura, Kazuhiro¹ (AUTHOR) k.kimura@yamaguchi-u.ac.jp

Source: Scientific Reports. 12/27/2023, Vol. 13 Issue 1, p1-11. 11p.

Subject Terms: *MACULAR edema, *RANIBIZUMAB, *ENDOTHELIAL growth factors, *LASER therapy, *OPTICAL coherence tomography, *THERAPEUTICS, *VISUAL acuity

Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography.

Authors: Wu, Lei¹ (AUTHOR), Li, Manhong¹ (AUTHOR), Wang, Liang¹ (AUTHOR), Yan, Hongxiang¹ (AUTHOR), Zhou, Ziyi¹ (AUTHOR), Fan, Jing¹ (AUTHOR), Zhou, Yi¹ (AUTHOR), Gou, Kaili¹ (AUTHOR), Guo, Changmei¹ (AUTHOR), Wang, Yusheng¹ (AUTHOR) wangys003@126.com, Zhang, Zifeng¹ (AUTHOR) zzffmmu@163.com

Source: Scientific Reports. 11/15/2023, Vol. 13 Issue 1, p1-9. 9p.

Subject Terms: *RANIBIZUMAB, *FLUORESCENCE angiography, *RETROLENTAL fibroplasia, *TORTUOSITY

Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery.

Authors: Wu, Kevin Y.¹ (AUTHOR) yang.wu@usherbrooke.ca, Fujioka, Jamie K.² (AUTHOR), Gholamian, Tara³ (AUTHOR), Zaharia, Marian¹ (AUTHOR), Tran, Simon D.⁴ (AUTHOR) simon.tran@mcgill.ca

Source: Pharmaceuticals (14248247). Sep2023, Vol. 16 Issue 9, p1241. 73p.

Subject Terms: *TARGETED drug delivery, *RANIBIZUMAB, *INTRAVITREAL injections, *TECHNOLOGICAL innovations, *INJECTIONS, *EYE drops, *INTRAOCULAR pressure, *SCLERA

Refractive status and retinal morphology in children with a history of intravitreal ranibizumab for retinopathy of prematurity.

Authors: Cheng, Haixia^1,2 (AUTHOR), Cao, Di^2,3 (AUTHOR), Qian, Jing¹ (AUTHOR), Gu, Wei⁴ (AUTHOR), Zheng, Zhi^2,5 (AUTHOR) zzheng88@sjtu.edu.cn, Ma, Mingming⁵ (AUTHOR) maming.ophth@sjtu.edu.cn

Source: European Journal of Pediatrics. Jul2023, Vol. 182 Issue 7, p3121-3128. 8p. 4 Charts, 1 Graph.

Subject Terms: *RETROLENTAL fibroplasia, *RANIBIZUMAB, *NERVE fibers, *LASER therapy, *MORPHOLOGY

Understanding in-vivo refolding of antibody fragments (Fab): Biosimilar Ranibizumab a case study.

Authors: Tungekar, Aatir A.^1,2 (AUTHOR), Fulewar, Padmaja¹ (AUTHOR), Kumthekar, Rupali^1,3 (AUTHOR), Bhambure, Rahul^1,3 (AUTHOR) rs.bhambure@ncl.res.in

Source: Process Biochemistry. Nov2024, Vol. 146, p484-497. 14p.

Subject Terms: *ESCHERICHIA coli, *RANIBIZUMAB, *CELL proliferation, *BIOLOGICAL assay, *IN vivo studies

A novel retinoic acid drug, EYE-502, inhibits choroidal neovascularization by targeting endothelial cells and pericytes.

Authors: Shen, Yaming¹ (AUTHOR), Xu, Miao¹ (AUTHOR), Ren, Ling² (AUTHOR), Li, Xiumiao³ (AUTHOR), Han, Xiaoyan² (AUTHOR), Cao, Xin⁴ (AUTHOR) caox@fudan.edu.cn, Yao, Jin^1,3 (AUTHOR) jinyao1972@126.com, Yan, Biao² (AUTHOR) biao.yan@fdeent.org

Source: Scientific Reports. 6/27/2023, Vol. 13 Issue 1, p1-16. 16p.

Subject Terms: *RANIBIZUMAB, *ENDOTHELIAL cells, *TRETINOIN, *PERICYTES, *MACULAR degeneration, *RETINOIC acid receptors, *NEOVASCULARIZATION

Polytherapy and Multimorbidity Pattern of Users of Anti-VEGF Drugs and Dexamethasone for the Treatment of Age-Related Macular Degeneration and other Vascular Retinopathies in Clinical Practice.

Authors: Lucenteforte, Ersilia¹ (AUTHOR) ersilia.lucenteforte@unipi.it, Finocchietti, Marco² (AUTHOR) m.finocchietti@deplazio.it, Addis, Antonio² (AUTHOR) a.addis@deplazio.it, Tettamanti, Mauro³ (AUTHOR) mauro.tettamanti@marionegri.it, Varano, Monica⁴ (AUTHOR) monica.varano@fondazionebietti.it, Parravano, Mariacristina⁴ (AUTHOR) mcparravano@gmail.com, Virgili, Gianni⁵ (AUTHOR) gianni.virgili@unifi.it

Source: Pharmaceuticals (14248247). May2023, Vol. 16 Issue 5, p646. 11p.

Subject Terms: *RANIBIZUMAB, *MACULAR degeneration, *COMORBIDITY, *CONCOMITANT drugs, *DRUG abusers, *INTRAVITREAL injections

Geographic Terms: LAZIO (Italy), ITALY

International consortium for innovation and quality: An industry perspective on the nonclinical and early clinical development of intravitreal drugs.

Authors: Pruimboom‐Brees, Ingrid M.¹ (AUTHOR) ingrid.pruimboom@novartis.com, Gupta, Swati² (AUTHOR), Chemuturi, Nagendra³ (AUTHOR), Booler, Helen S.¹ (AUTHOR), Nimz, Erik^1,4 (AUTHOR), Ferrell Ramos, Meg² (AUTHOR), Caruso, Antonello⁵ (AUTHOR), Maass, Katie F.⁶ (AUTHOR), Bantseev, Vladimir⁶ (AUTHOR), Huang, Qihong⁷ (AUTHOR), Choules, Mary P.⁸ (AUTHOR), Nussbaum, Jesse C.⁹ (AUTHOR), Kanodia, Jitendra¹⁰ (AUTHOR), Thompson, Christopher¹¹ (AUTHOR), Durairaj, Chandrasekar³ (AUTHOR) chandra.durairaj@takeda.com

Source: CTS: Clinical & Translational Science. May2023, Vol. 16 Issue 5, p723-741. 19p.

Subject Terms: *RANIBIZUMAB, *MACULAR degeneration, *DRUG development, *CONSORTIA, *VISION disorders, *MACULAR edema

Clinical and Histopathological Effects of Intracameral Ranibizumab in Experimental Trabeculectomy.

Authors: Azhany, Yaakub^1,2 (AUTHOR) azhany@usm.my, Rahman, Wan Faiziah Wan Abdul³ (AUTHOR), Jaafar, Hasnan³ (AUTHOR), Low, Jen Hou⁴ (AUTHOR), Yusuf, Wan Nazirah Wan⁴ (AUTHOR), Liza-Sharmini, Ahmad-Tajudin² (AUTHOR), Che Hamzah, Jemaima¹ (AUTHOR) azhany@usm.my

Source: International Journal of Molecular Sciences. Apr2023, Vol. 24 Issue 8, p7372. 13p.

Subject Terms: *TRABECULECTOMY, *RANIBIZUMAB, *TREATMENT effectiveness, *HEMATOXYLIN & eosin staining, *MITOMYCIN C

Comparative Treatment Study on Macular Edema Secondary to Branch Retinal Vein Occlusion by Intravitreal Ranibizumab with and without Selective Retina Therapy.

Authors: Yamamoto, Manabu¹ (AUTHOR) myamamoto1977@gmail.com, Miura, Yoko^2,3,4 (AUTHOR), Hirayama, Kumiko¹ (AUTHOR), Kyo, Akika¹ (AUTHOR), Kohno, Takeya¹ (AUTHOR), Theisen-Kunde, Dirk⁴ (AUTHOR), Brinkmann, Ralf^2,4 (AUTHOR), Honda, Shigeru¹ (AUTHOR)

Source: Life (2075-1729). Mar2023, Vol. 13 Issue 3, p769. 12p.

Subject Terms: *RANIBIZUMAB, *RETINAL vein occlusion, *MACULAR edema, *MACULA lutea, *BEVACIZUMAB, *RETINA, *INTRAVITREAL injections, *VISUAL acuity

Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity.

Authors: Prajapati, Vipul¹ (AUTHOR), Choudhary, Tanvi¹ (AUTHOR), Chauhan, Wilhemina¹ (AUTHOR), Shah, Sonali¹ (AUTHOR), Handa, Ramya¹ (AUTHOR), Jahan, Bushra¹ (AUTHOR), Malviya, Sheetal¹ (AUTHOR), Sengupta, Sabyasachi² (AUTHOR)

Source: Indian Journal of Ophthalmology. Feb2023, Vol. 71 Issue 2, p411-415. 5p.

Subject Terms: *RETROLENTAL fibroplasia, *RANIBIZUMAB, *LASER photocoagulation, *BIRTH weight, *GESTATIONAL age, *NEOVASCULARIZATION

Healing rate of macular edema secondary to branch retinal vein occlusion in two years after initiation of intravitreal ranibizumab later combined with other treatment as needed and characteristics of refractory cases.

Authors: Kawakami, Setsuko¹ (AUTHOR) setsu@tokyo-med.ac.jp, Wakabayashi, Yoshihiro¹ (AUTHOR), Watanabe, Yoko¹ (AUTHOR), Umazume, Kazuhiko¹ (AUTHOR), Yamamoto, Kaori¹ (AUTHOR), Goto, Hiroshi¹ (AUTHOR)

Source: PLoS ONE. 1/3/2023, Vol. 18 Issue 1, p1-8. 8p.

Subject Terms: *RANIBIZUMAB, *RETINAL vein occlusion, *MACULAR edema, *ENDOTHELIAL growth factors, *HEALING, *REFRACTORY materials

Release of ranibizumab using a porous poly(dimethylsiloxane) capsule suppressed laser-induced choroidal neovascularization via the transscleral route.

Authors: Nagai, Nobuhiro¹, nagai@med.tohoku.ac.jp, Daigaku, Reiko¹, Motoyama, Remi¹, Kaji, Hirokazu², Abe, Toshiaki¹

Source: Journal of Materials Science: Materials in Medicine; Jan2023, Vol. 34 Issue 1, p1-8, 8p